The HemOnc Pulse
The HemOnc Pulse is a podcast from Blood Cancers Today focused on hematologic oncology. It is hosted by Rahul Banerjee, MD, alongside HemOnc Pulse Live! hosts Naval G. Daver, MD and Mehdi H. Hamadani, MD. Episodes cover a wide range of topics in the world of blood cancer care, research and treatment. The show features expert discussion and commentary aimed at clinicians and others following the field.
Episodes
Rewriting the Treatment Playbook for MDS/MPN and Myelofibrosis
In this Editor’s Special episode of The HemOnc Pulse, MD Anderson Cancer Center’s Naval Daver, MD, and Naveen Pemmaraju, MD, discuss MDS/MPN overlap conditions and research examining combination therapy with ruxolitinib and azacitidine (AZA), including its potential to improve disease response, symptom control, and outcomes.
Taking Bispecific Antibodies Outpatient: Lessons From the Front Lines
How can bispecific antibodies be safely delivered outside the hospital? Rahul Banerjee, MD and Ajay Nooka, MD discuss outpatient step-up dosing, prophylactic tocilizumab, CRS management, and practical tips for implementing bispecific therapy in academic and community practice.
Community-Based CAR-T Therapy: Expanding Access, Navigating Challenges
In this episode of HemOnc Pulse, host Dr. Rahul Banerjee of Fred Hutchinson Cancer Center sits down with Dr. Gary Simmons, a hematologist-oncologist at Virginia Oncology Associates, to explore the evolving role of community-based cellular therapy programs and the future of patient access to innovative treatments.
Cutting GVHD Risk: What’s Changing in Allogeneic Transplants?
Learn how new approaches in allogeneic transplants, from PTCy to innovative regimens, are helping reduce GVHD and improve patient outcomes with special guest Sagar S. Patel, MD of University of Utah Health.
MRD at the Regulatory Crossroads in Multiple Myeloma
In this Editor’s Special Episode of The HemOncPulse, a conversation with Nicholas Richardson, DO, MPH, vice president of clinical development at Precision for Medicine, focuses on the evolving regulatory role of measurable residual disease in multiple myeloma clinical trials. The discussion is designed to contextualize recent FDA draft guidance for a broad clinical and research audience.
The Data Problem in T-Cell Lymphoma Care
In this episode of TheHemOnc Pulse, Rahul Banerjee, MD, speaks with Francine Foss, MD, professor of medicine and dermatology at Yale School of Medicine, about the evolving landscape of T-cell lymphomas. Dr Foss discusses the unique challenges of studying and treating rare diseases such as cutaneous T-cell lymphoma and explains why real-world data are essential to closing evidence gaps. The convers
XPO1 Inhibition Across the Myeloma Journey
This Editor’s Special Episode of The HemOnc Pulse features Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discussing treatment strategies for relapsed/refractory multiple myeloma and where selinexor-based regimens fit in today’s evolving landscape. Drawing from real-world cases, Dr. Richardson explores care for patients before CAR T, after CAR T relapse, and in between—highlightin
Holding the Line in AML: Real-World Care Meets Breakthrough Trials
Dr. Eunice Wang joins host Rahul Banerjee, MD, for a clinician-focused discussion on AML, treatment complexity, and real-world leukemia management in today’s evolving therapeutic landscape.
Under the Hood: Exploring the Genomic Engines of Smoldering Myeloma
In this episode of The HemOnc Pulse, host Melissa speaks with Omar Nadeem, MD, Senior Physician at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, about emerging genomic insights in smoldering multiple myeloma. The discussion focuses on recent research showing how molecular profiling can improve understanding of disease progression and refine risk
Toxicity, Time, and the Patient Experience in Blood Cancers
Dr. Rahul Banerjee interviews Dr. Ajay Major on patient-reported outcomes, toxicity reporting, and patient engagement in blood cancer clinical trials.
Editor's Special Episode: Future Directions in MPN Treatment with Dr. Hobbs
Dr. Hobbs joins the podcast to discuss the latest advances in myeloproliferative neoplasms (MPNs), including ropeginterferon and the VERIFY trial of rusfertide in polycythemia vera. He highlights key efficacy and safety data, unmet needs in essential thrombocythemia and myelofibrosis, and the next wave of clinical trials to watch.
Clinical Advances in Myeloma: A Nordic Perspective
Host Rahul Banerjee, MD, speaks with Drs. Frederik Schjesvold and Frida Askeland on myeloma trial results, relevance in the IMROZ/CEPHEUS era, and advances in treating elderly, frail patients.
Grand Rounds in Leukemia: MD Anderson Fellows on AML Endpoints
MD Anderson fellows discuss AML, MRD endpoints, and evolving trial strategies in a dynamic grand rounds–style presentation.
Editor’s Special Episode: Progress and Prospects in CLL Management
William Wierda, MD, PhD of the University of Texas MD Anderson discusses advances in chronic lymphocytic leukemia care, from targeted therapies and resistance to immune dysfunction and prevention with Blood Cancers Today Managing Editor, Nichole Tucker.
Today’s Clinical Trials Define the Next Era in Myeloma
In this Editor’s Special Episode of The HemOnc Pulse, Dr. Hira Mian of McMaster University shares expert insights on the evolving treatment landscape for multiple myeloma. From optimizing selinexor use, to understanding long-term MonumenTAL-1 data with talquetamab, to the promise of emerging trispecific antibodies, Dr. Mian highlights the biggest shifts shaping care today.
‘The HemOnc Pulse Live:’ Transforming ALL Treatment Pathways
A panel of hematology leaders discusses the latest in ALL and T-cell ALL therapy, including TKI+blina combinations, venetoclax strategies, and the emerging role of CD7 CAR T-cell therapies in reshaping treatment paradigms.
Evolving Approaches in the Management of MDS
Review of IMerge phase 3 data on imetelstat for lower-risk MDS and how prior therapies affect treatment outcomes, and other ASCO 2025 MDS updates with Andrew Brunner, MD.
‘The HemOnc Pulse Live!’: AML in Transition
During a session at The HemOnc Pulse Live! moderated by Naval Daver, MD, Eunice Wang, MD presents new insights in acute myeloid leukemia care, joined by Aditi Shastri, MBBS, Tapan Kadiya, MD, and Kelly Chien, MD for a rich panel on mutation loss, minimal residual disease, and transplant timing.
From Trials to Practice: What's New and What's Next for Myeloma
Drs. Gurbakhash Kaur and Danai Dima discuss next-gen CAR T and bispecific therapies for myeloma, including agents for extramedullary disease and GPRC5D targets.
Editor’s Special Episode: Innovations in B-NHL
In this Editor’s Special of The HemOnc Pulse, Tycel Phillips, MD, joins an editor of Blood Cancers Today to break down the latest research in B-cell non-Hodgkin lymphoma presented at the 2025 ASCO Annual Meeting. The conversation spans follicular lymphoma, CLL, mantle cell lymphoma, and large B-cell lymphoma, covering key insights on BTK/BCL2 inhibitors, bispecifics, CAR T-cell therapy, an
Editor’s Special Episode: Treating CLL Now and in the Future
Hematologist-oncologist Dr. Alexey Danilov shares expert insights on chronic lymphocytic leukemia, highlighting unmet needs in immune management, the challenges of Richter’s transformation, and promising data on BTK degraders for double-refractory patients.
'The HemOnc Pulse Live': Controversies in Frontline Myeloma
Saad Usmani, MD, MBA leads an in-depth discussion with a panel of leading myeloma experts; Dr. Caitlin Costello, Dr. Binod Dhakal, Dr. Pete Voorhees, and Dr. Shambavi Richard on the evolving landscape of frontline multiple myeloma treatment. The conversation covers the rationale behind quadruplet therapy, the integration of minimal residual disease as a response-adaptive strategy, and shi
Editor’s Special Episode: ASCO 2025 Highlights in AML with Dr. Amir Fathi
In this Editor’s Special of The HemOnc Pulse, Blood Cancers Today Managing Editor, Nichole Tucker speaks with Amir Fathi, MD, of Massachusetts General Hospital, about key updates in AML from ASCO 2025. The discussion centers on a phase 2 study of an all-oral regimen—decitabine and cedazuridine plus venetoclax—for patients with newly diagnosed AML who are unfit for intensive induction.
Dr. Fathi di
Navigating Drug Accessibility in Cancer Care
In this episode of The Hem Onc Pulse, Dr. Rahul Banerjee is joined by Dr. Michelle Longmire, CEO and co-founder of Medable, for a compelling discussion on drug accessibility in cancer care. Together, they explore how decentralized clinical trials and digital tools can help bridge the gap between cutting-edge therapies and the patients who need them most. Dr. Longmire shares how Medable is
The 'HemOnc Pulse Live' Controversies in Aggressive NHL
In this HemOnc Pulse Live! edition of podcast, Dr. Mehdi Hamadani leads a comprehensive panel discussion on controversies and unanswered questions in the treatment of aggressive non-Hodgkin lymphoma. Dr. Hamadani is joined by Drs. Timothy Fenske, Madiha Iqbal, Urshila Durani, and Mohamed Kharfan-Dabaja.
Inside the War on Myeloid Malignancies: Early Clues & Bold Innovations
In this episode of HemOnc Pulse, host Rahul Banerjee, MD, FACP of Fred Hutch Cancer Center is joined by myeloid malignancy expert Uma Borate, MBBS of The Ohio State University, for a high-impact discussion on one of hematology’s hottest frontiers: early detection. As aggressive diseases like AML and MDS continue to outpace traditional diagnostics, this conversation dives into why spotting thes
'The HemOnc Pulse' Live 2025: Controversies in MDS
In this special episode of our podcast, recorded live at HemOnc Pulse Live in Austin, Texas on May 2–3, 2025, leading experts tackle some of the most pressing controversies in the management of myelodysplastic syndromes. Moderated by Naval Daver, MD, this dynamic panel discussion brings together top thought leaders in hematologic malignancies to debate evolving treatment standards, diagnostic chal
Redirected Strategy: Tal and TEC in the Myeloma Mix
In this episode of The HemOnc Pulse, Rahul Banerjee, MD of Fred Hutchinson Cancer Center is joined by Gurbakhash Kaur, MD of Mount Sinai for an in-depth discussion of the RedirecTT-1 trial, recently published in the New England Journal of Medicine. The conversation explores the evolving role of bispecific antibodies in multiple myeloma, with a focus on the combination of talquetamab (Tal) and tecl
Dr. Usmani Highlights Myeloma Presentations from SOHO 2024
On this episode of "The HemOnc Pulse," Saad Usmani, MD, of the Memorial Sloan Kettering Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss notable presentations on multiple myeloma from the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.
Covering MDS Updates at SOHO 2024 With Dr. Venugopal
On this episode of "The HemOnc Pulse," Chadi Nabhan, MD, MBA, FACP, is joined by Sangeetha Venugopal, MD, of the Sylvester Comprehensive Cancer Center at the University of Miami, to highlight data on myelodysplastic syndromes (MDS) presented at the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.
AML News From SOHO 2024 With Dr. Daver
On this episode of "The HemOnc Pulse," Naval Daver, MD, of the MD Anderson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss news on acute myeloid leukemia coming out of the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.
Dr. Shadman Shares SOHO 2024 Data On CLL
On this episode of "The HemOnc Pulse," Mazyar Shadman, MD, MPH, of the Fred Hutchinson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to highlight some of the notable presentations on chronic lymphocytic leukemia coming out of the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.
Dr. Bose on MPN Highlights From SOHO 2024
On this episode of "The HemOnc Pulse," Prithviraj Bose, MD, of the University of Texas MD Anderson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss some of the important data on myeloproliferative neoplasms that were presented at the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.
Part Two: The Question of MRD in CLL Therapy
In part two of this episode, Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center; Meghan Thompson, MD, of Memorial Sloan Kettering Cancer Center; and Alan Skarbnik, MD, of Novant Health, continue to explore the role of measurable residual disease (MRD) in the treatment of patients with chronic lymphocytic leukemia (CLL).
“The HemOnc Pulse” was live for in Chicago, Illinois, on May 3-4 and fe
Dr. Osman on Identifying and Treating High-Risk MDS
On “The HemOnc Pulse,” Chadi Nabhan, MD, MBA, FACP, met with Afaf Osman, MD, an Assistant Professor at the University of Utah Huntsman Cancer Center, to discuss how high-risk myelodysplastic syndromes (MDS) are distinct from lower-risk classifications and how to approach treatment.
Dr. Rami Komrokji on Trends in Real-World MDS Care
On “The HemOnc Pulse,” Chadi Nabhan, MD, MBA, FACP, spoke with Rami Komrokji, MD, Vice Chair of the Malignant Hematology Department at Moffitt Cancer Center in Tampa, Florida, about the state of myelodysplastic syndromes (MDS) care. Moffitt Cancer Center is home to a large MDS database, with clinical information on nearly 6,000 patients, a trove of real-world MDS data.
Part One: The Question of MRD in CLL Therapy
Part one of this episode explores questions in measurable residual disease (MRD) and chronic lymphocytic leukemia (CLL) with Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center; Meghan Thompson, MD, of Memorial Sloan Kettering Cancer Center; and Alan Skarbnik, MD, of Novant Health.
“The HemOnc Pulse” was live for in Chicago, Illinois, on May 3-4 and featured host Chadi Nabhan, MD, MBA, FACP,
‘The HemOnc Pulse’ Live: Unanswered Questions in T-Cell Lymphoma
At the “HemOnc Pulse” Live meeting in Chicago, an expert panel explores unanswered questions in T-cell lymphoma management. The panelists were Mehdi Hamadani, MD, a Professor of Internal Medicine at the Medical College of Wisconsin, Andrew Evens, DO, MBA, MSc, Deputy Director for Clinical Services at Rutgers Cancer Center, and Barbara Pro, MD, a Professor of Medicine at Columbia University Vagelos
‘The HemOnc Pulse’ Live 2024: Is it Time for New Endpoints in MPN?
Recorded at the first annual “HemOnc Pulse” Live meeting, this episode features a panel discussion on unanswered questions in myeloproliferative neoplasms (MPN) with Naveen Pemmaraju, MD, of the University of Texas MD Anderson Cancer Center; Ruben Mesa, MD, of the Atrium Health cancer service line; Sanam Loghavi, MD, of the MD Anderson Cancer Center; and Olatoyosi Odenike, MD, of the University of
Unpacking Bispecifics at ‘The HemOnc Pulse’ Live Meeting
“The HemOnc Pulse” was live for the first time in Chicago, Illinois, on May 3-4 and featured host Chadi Nabhan, MD, MBA, FACP, moderating panels of academic and clinical experts who delved into unanswered questions in a range of hematologic malignancies. As part of the program, Michael Bishop MD, of the University of Chicago, and Aaron Goodman, MD, of the University of California, San Diego, were
'The HemOnc Pulse' Live: Unanswered Questions in Treating DLBCL
In this podcast episode covering the “HemOnc Pulse” Live meeting in Chicago, an expert panel explores unanswered questions in managing diffuse large B-cell lymphoma. The panelists included Grzegorz Nowakowski, MD, a Professor of Oncology and Medicine in the Division of Hematology at the Mayo Clinic; Jane Winter, MD, a Professor of Medicine in the Division of Hematology and Oncology at the Northwes
‘The HemOnc Pulse’ Live 2024: Unanswered Questions in CML Treatment
Recorded at the first “HemOnc Pulse” Live meeting in Chicago, this podcast episode features a panel discussion on unanswered questions in chronic myeloid leukemia (CML) with Elias Jabbour, MD, a Professor of Medicine in the Department of Leukemia at the University of Texas MD Anderson Cancer Center; Mikkael Sekeres, MD, MS, a Professor of Medicine and Chief of the Division of Hematology at the Uni
‘The HemOnc Pulse’ Live: What Are the Unanswered Questions in ALL?
Recorded at the first “HemOnc Pulse” annual meeting, this podcast episode features a panel discussion on unanswered questions in acute lymphoblastic leukemia (ALL) with Elias Jabbour, MD, a Professor of Medicine at the University of Texas MD Anderson Cancer Center; Shira Dinner, MD, an Associate Professor of Medicine (Hematology and Oncology) at Northwestern Medicine; Sanam Loghavi, MD, an Associa
Discussing the Role of MRD in CLL With Talal Hilal, MD
Dr. Hilal, of the Mayo Clinic, joins Chadi Nabhan, MD, MBA, FACP, on “The HemOnc Pulse” to discuss measurable residual disease (MRD) and the debates surrounding its use for response assessment in patients with chronic lymphocytic leukemia (CLL).
‘The HemOnc Pulse’ Live 2024: How Is Hodgkin Lymphoma Treated?
Recorded at the first “HemOnc Pulse” Live meeting, this podcast episode features a panel discussion on unanswered questions in Hodgkin lymphoma with Andrew Evens, DO, MBA, MSc, Director of the Lymphoma Program and Associate Director of Rutgers Cancer Institute; Grzegorz Nowakowski, MD, a Professor of Oncology and Medicine in Division of Hematology at the Mayo Clinic; and Jane Winter, MD, a Profess
Unanswered Questions in MDS at ‘The HemOnc Pulse’ Live 2024 in Chicago
Recorded at the first “HemOnc Pulse” Live meeting, this podcast episode features a panel discussion on unanswered questions in myelodysplastic syndromes (MDS) with Rami Komrokji, MD, Vice-Chair of the Malignant Hematology Department at Moffitt Cancer Center; Sanam Loghavi, MD, an Associate Professor of Pathology at the University of Texas MD Anderson Cancer Center; Jamile Shammo, MD, FACP, FASCP,
‘The HemOnc Pulse Live’ in Chicago: Fellows Discuss Choosing a Career Path in Hematology Oncology
This podcast episode features a panel discussion on challenges and opportunities for hematology oncology fellows with Megan Melody, MD, a third-year fellow at Northwestern University; Alexandra Rojek, MD, a second-year fellow at the University of Chicago Medicine Comprehensive Care Center; Seda Tolu, MD, a third-year fellow at the Columbia University Herbert Irving Comprehensive Cancer Center; Zak
“The HemOnc Pulse” Live 2024 in Chicago: CAR-T Unanswered Questions
“The HemOnc Pulse” goes on the road to Chicago May 3-4 with host Chadi Nabhan, MD, MBA, FACP, for the first live meeting.
This podcast episode features a panel discussion on unanswered questions in chimeric antigen receptor (CAR) T-cell therapy with Caron Jacobson, MD, MMSc, Medical Director of the Immune Effector Cell Therapy Program at Dana-Farber Cancer Institute; Michael Bishop, MD, FACP, FASC
"The HemOnc Pulse" Live 2024 in Chicago: AML Unanswered Questions
"The HemOnc Pulse" goes on the road to Chicago with host Chadi Nabhan, MD, MBA, FACP.
This podcast episode features a panel discussion on unanswered questions in acute myeloid leukemia (AML) with Naval Daver, MD, an Associate Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center; Sanam Loghavi, MD, of the MD Anderson Cancer Center; Rami Komrokji, MD, the Vice
What are the Controversies Surrounding MRD in Blood Cancers?
On this episode of "The HemOnc Pulse," Alan Skarbnik, MD, of Novant Health, and Manni Mohyuddin, MBBS, of the University of Utah, discuss the concept of measurable residual disease (MRD) in hematologic malignancies and highlight the polarized views surrounding MRD.
They also weigh the implications of MRD negativity, how to harmonize the MRD threshold, and how trials are putting MRD technology to t
HMAs Are ‘Cornerstone’ of High-Risk MDS Treatment, Says Jamile Shammo, MD
On this episode of “The HemOnc Pulse,” Dr. Shammo, a Professor of Medicine in Hematology and Oncology at Northwestern Medicine, discusses how to approach treatment for myelodysplastic syndromes (MDS).
Dr. Shammo speaks on everything from low- to high-risk treatment of patients with MDS, including why hypomethylating agents are the cornerstone for treating high-risk patients with MDS.
Krish Patel, MD, Talks Glofitamab, Other Novel Therapies in DLBCL
Dr. Patel, of the Swedish Cancer Institute in Seattle, Washington, joins Chadi Nabhan, MD, MBA, FACP, on “The HemOnc Pulse” to discuss novel frontline therapies in the lymphoma space, including the bispecific antibody glofitamab.
They also discuss bispecifics versus chimeric antigen receptor (CAR) T-cell therapy, fixed duration therapy and step-up dosing, and how to sequence therapy.
Aaron Goodman, MD, Tells Us the 'Crux' of Castleman Disease
In this episode of "The HemOnc Pulse," Dr. Goodman, an Associate Professor of Medicine at the University of California San Diego, joins Chadi Nabhan, MD, MBA, FACP, to discuss Castleman Disease.
Dr. Goodman explains why the rare disease is often mismanaged, how each subtype is diagnosed and treated, and how it's comparable to hematologic cancers like lymphoma or myeloma.
Is MRD Negativity the New Benchmark in ALL Treatment Strategies?
Elias Jabbour, MD, an Executive Editor of Blood Cancers Today and a Professor of Leukemia at the University of Texas MD Anderson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss the function of measurable residual disease in treating acute lymphocytic leukemia (ALL) and other progress that has been made in treating patients with Philadelphia chromosome-positive and Philadelphia chromos
Part Two: Drs. Dahiya, Spiegel Return to Discuss 'Black Box' Warning on CAR-T Therapies
Saurabh Dahiya, MD, FACP, of Stanford Medicine, and Jay Spiegel, MD, of the University of Miami, join The HemOnc Pulse for the second half of a two-part series on reports regarding secondary T-cell malignancies in patients after being treated with a chimeric antigen receptor (CAR) T-cell therapy and updates from the US Food and Drug Administration (FDA) on the issue.
Drs. Dahiya and Spiegel return
Dr. Coombs Spotlights Recent CHIP Updates
In this season's fourth episode of "The HemOnc Pulse," Catherine Coombs, MD, an Associate Professor in the Division of Hematology/Oncology at the University of California, Irvine, School of Medicine, highlights recent studies in clonal hematopoiesis of indeterminate potential (CHIP) presented at the 65th American Society of Hematology Meeting & Exposition.
Dr. Coombs discusses research on reve
Drs. Dahiya, Spiegel Discuss CAR-T Secondary Malignancies Risk
An all-new episode of The HemOnc Pulse with Saurabh Dahiya, MD, FACP, of Stanford Medicine, and Jay Spiegel, MD, of the University of Miami, features a discussion on the link between chimeric antigen receptor (CAR)-T cell therapies and secondary T-cell malignancies. The episode follows on the heels of the US Food and Drug Administration's request to drug manufacturers of the six CAR-T therapie
Aditi Shastri, MD: Clinicians Need to ‘Come Together’ on TP53-Mutated MDS
This episode features a conversation between Dr. Shastri, an Assistant Professor of Medicine at the Montefiore Einstein Comprehensive Cancer Center in the Bronx, New York, and The HemOnc Pulse host, Chadi Nabhan; MD; MBA; FACP; on the latest news in myelodysplastic syndromes (MDS), including the final readout from the COMMANDS trial and the clinical implications of TP53-mutated MDS.
What It Takes to Harmonize the World’s Hodgkin Lymphoma Data
The first episode of The HemOnc Pulse of the new year features an in-depth discussion by the leading researchers of the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) consortium.
Principal investigators Susan Parsons, MD, MRP; and Andrew Evans, DO, MBA, MSc; are joined by Matthew Maurer, DMSc; to share the story behind harmonizing the world's Hodgkin lymphoma data, and what t
Dr. Usmani Discusses Perseus, IsKia, Data Plus More Myeloma Updates
Saad Usmani, MD, MBA, FACP, Chief of the Myeloma Service at the Memorial Sloan Kettering Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, on The HemOnc Pulse to chat about the latest research in multiple myeloma from the 65th American Society of Hematology (ASH) Annual Meeting and Exposition.
Dr. Usmani shares insights on the evolution in myeloma treatment since he first started practicing in t
Dr. Venugopal Offers Her Thoughts on the Latest MDS News
Sangeetha Venugopal, MD, of the University of Miami Sylvester Comprehensive Cancer Center, offers her thoughts on the investigational drug KER-050 in lower-risk myelodysplastic syndromes (MDS), the COMMANDS trial, and if she believes MDS is a distinct disease.
She also highlights the latest research in MDS at the 65th American Society of Hematology Annual Meeting and Exposition.
Jerald Radich, MD: AML Abstracts to Keep an Eye on at ASH 2023
In this episode of The HemOnc Pulse, Jerald Radich, MD, of the Fred Hutchinson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss various abstracts on acute myeloid leukemia (AML) presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition. The conversation centered around menin inhibitors for the treatment of AML, the effect of measurable residual disease-
Inside the FDA ODAC ’Yes’ Vote to Polivy
In this episode of The HemOnc Pulse, Grzegorz Nowakowski MD, a Professor of Oncology and Medicine in the Division of Hematology at the Mayo Clinic, recounts his experience serving on the FDA Oncologic Drugs Advisory Committee that reviewed and evaluated data from the POLARIX study and polatuzumab vedotin-piiq (Polivy)for patients with previously untreated LBCL.
Kami Maddocks, MD, on the Shocking Ibrutinib Withdrawal
In this episode of The HemOnc Pulse, Dr. Maddocks, Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University, charts the treatment evolution of mantle cell lymphoma (MCL) from frontline therapy to future directions. She also explains her initial shock, and subsequent bittersweet reaction to the withdrawal of ibrutinib.
Jorge Cortes, MD, on Why Balance Is Key in CML Therapy
Dr. Cortes, who serves as Director of the Georgia Cancer Center at Augusta University, joins host Chadi Nabhan, MD, MBA, FACP, to chat about the “boom” in treatments for chronic myeloid leukemia (CML), and where he sees a need for balance.
Dr. Cortes discussed the evolution of tyrosine kinase inhibitors (TKIs) and the multiple generations of TKIs that are now available. Second-generation TKIs ca
What Are the Top Questions in ALL?
Elias Jabbour, MD, of the University of MD Anderson Cancer Center stops by The HemOnc Pulse for a live show at the Eleventh Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.
In this episode, Dr. Jabbour, who is also an Associate Editor of Blood Cancers Today, the home of The HemOnc Pulse, discusses the most burning questions in acute lymphoblastic leukemia (ALL).
The ABCs of MM Treatment According to Rafael Fonseca, MD
Dr. Fonseca offers his thoughts on the future of multiple myeloma (MM) treatment, the ongoing debate between chimeric antigen receptor (CAR)-T therapies and bispecifics, and the latest treatment news on bispecifics, including elranatamab, which had yet to be approved at the time of this recording.
The conversation also covers the role of measurable residual disease (MRD), the potential for bispec
The Post-POLARIX Trial Era: Polatuzumab Vedotin Shifts DLBCL Treatment
On this episode of The HemOnc Pulse, guest Jonathan Friedberg, MD, MMSc, a hematologic oncologist at the University of Rochester Medicine – Wilmot Cancer Institute, chats with host Dr. Chadi Nabhan on the subtle but important shift in the treatment landscape of diffuse large B-cell lymphoma (DLBCL)in the post-POLARIX trial era.
The POLARIX trial, which was designed to improve upon the standard R-
Dr. Garcia-Manero on the Data Behind the Luspatercept Approval
Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, live at the Eleventh Annual Meeting of the Society of Hematologic Oncology to discuss the phase III COMMANDS trial, the recent approval of luspatercept, and other developments in myelodysplastic syndromes (MDS) treatment and research.
Dr. Garcia-Manero spoke about the design of th
Mazyar Shadman, MD, MPH, Reports the Latest BTKi News in CLL
Dr. Shadman of the Fred Hutchinson Cancer Center in Seattle rounds up the latest news in chronic lymphocytic leukemia (CLL) from the summer conferences, including updates on novel Bruton tyrosine kinase inhibitor (BTKi) therapies in CLL.
Bhavana Bhatnagar, MD, on the Molecular Revolution in AML
In this episode of The HemOnc Pulse, Dr. Bhatnagar, an Associate Professor of Medicine at the West Virigina University Cancer Institute, reflects on how the molecular characterization of acute myeloid leukemia (AML) has evolved. She joins host Chadi Nabhan, MD, MBA, FACP, to discuss how this growing base of knowledge has impacted diagnosis, treatment, and classification.
“The most significant cha
Do Venetoclax Combinations Trump Chemotherapy in Frontline CLL Treatment?
Is there a venetoclax combination that reigns supreme in chronic lymphocytic leukemia (CLL)? Is venetoclax-based therapy the way to go in treating frontline CLL? Nitin Jain, MD, of the University of Texas MD Anderson Cancer Center, shares his thoughts on these questions and recent data published in the New England Journal of Medicine.
Why Grzegorz Nowakowski, MD, Says There’s a ‘Revolution’ in LBCL Therapy
Dr. Nowakowski, a Professor of Oncology and Medicine in the Division of Hematology at the Mayo Clinic, talks about the revolution in treatment options in diffuse large B-cell lymphoma(DLBCL).
"The last couple of years, we've seen quite a revolution in the treatment of DLBCL," he said. "We have multiple approved therapies now, and more coming, so it's really a very rapidly changing field."
He al
An Expert’s Look into the World of Rare Blood Cancers
Naveen Pemmaraju, MD, Associate Professor at the University of Texas MD Anderson Cancer Center, talks about the rare, ultrarare, and forgotten blood cancers, including his lifelong work in blastic plasmacytoid dendritic cell neoplasm (BPDCN), in this episode of The HemOnc Pulse.
The Logistics of CAR-T in Hematologic Malignancies
Navneet Majhail, MD, MS, the Physician in Chief at Sarah Cannon in Nashville, Tennessee, delves into the intricacies of chimeric antigen receptor (CAR) T-cell therapy, discussing the logistics and challenges involved with these therapies.
Dr. Majhail explores strategies to improve access to CAR-T therapy and he discusses the role of CAR-T amidst the availability of bispecific antibodies as treat
Abi Vijenthira, MD, and Anca Prica, MD, on Why Certain DLBCL Therapies May Not Be Cost Effective
Drs. Vijenthira and Prica, both of the Princess Margaret Cancer Centre, speak with host Chadi Nabhan, MD, MBA, FACP, about their analysis on the cost-effectiveness of pola-R-CHP and second-line CAR-T in patients with DLBCL, and why its results differed from a similar study published in the journal Blood in December 2022.
Sagar Lonial, MD, FACP, on Why This MRD Approach Is ’Premature’ in MM
Blood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, discusses how he approaches frontline therapy for multiple myeloma (MM), why he thinks certain approaches to minimal residual disease (MRD) in MM are “premature,” and the data that show why sustained MRD negativity is key, with host Chadi Nabhan, MD, MBA, FACP.
Alan Skarbnik, MD, Gives the Lowdown on Treating Patients with Follicular Lymphoma
Alan Skarbnik, MD, of Novant Health, discusses treating patients with follicular lymphoma, the nuances involved in those decisions, and why bispecifics are here to stay, with host Chadi Nabhan, MD, MBA, FACP.
Amer Zeidan, MBBS, MHS, on the Evolution of AML Classification, Treatment
In this episode of The HemOnc Pulse, Amer Zeidan, MBBS, MHS, of Yale, discusses the impact of AML classification updates, the practical implications of testing for genetic alterations, and how patient characteristics inform his approach to treating AML, with host Chadi Nabhan, MD, MBA, FACP.
What Is the Cost-Effectiveness of Pola-R-CHP in DLBCL?
Swetha Kambhampati, MD, and Nikhil Thiruvengadam, MD, discuss the implications of their study investigating the cost-effectiveness of pola-R-CHP in previously untreated DLBCL.
Recommended
The Healer Revolution
Becoming: HER with Nikki Spoelstra
Booked, Blonde & Busy w/ Olivia Ponton
McKinsey on Consumer and Retail
megahired.com
Hard Knocks Podcast
Effective Weight Loss for Moms | High protein, Strength Training, Lose Weight, Meal Planning, Fat Loss, Healthy Habits
The Human-Animal Connection - Pet Life Radio Original
Infinite Health with Dr. Arasi Maran
The Daily
World News Tonight with David Muir
The Joe Rogan Experience
